Car-T Central
  • CAR-T Fundamentals
  • CAR-T in Australia
  • Clinical Management
  • Expert Opinion
  • About Us
  • Register
Car-T Central
  • CAR-T Fundamentals
  • CAR-T in Australia
  • Clinical Management
  • Expert Opinion
  • About Us
  • Register

ASH

CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, A B-Cell Maturation Antigen Directed Chimeric Antigen Receptor T cell Therapy, in Relapsed/Refractory Multiple Myeloma.

Preliminary results indicate  that anti-BCMA CAR-T cell therapy, ciltacabtagene autleucel (cilta-cel), resulted in early, deep and durable responses in heavily pre-treated patients with MM.   ORR was , sCR .  Durability […]

Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

This is an updated analysis of Zuma 5 – the CAR-T study of Axi-cel in follicular lymphoma (FL) and marginal zone lymphoma (MZL), initially reported in the mid-year conference season. […]

Interim Analysis of ZUMA-12: A Phase 2 study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients with High-Risk Large B Cell Lymphoma (LBCL).

ZUMA-12 is the first study evaluating CAR T therapy first-line in high-risk LBCL. The results demonstrated an ORR of 85% and a CR in 74% of patients treated with Axi-Cel. […]

Phase I Trial of MB-CART2019.1, a Novel CD20 and CD19 Targeting Tandem Chimeric Antigen Receptor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

This is the first phase 1 study to explore dual antigen-targeting CAR-T cells in DLBCL. The very preliminary phase 1 data suggests several agents will be pushing to larger trials. […]

Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in TRANSCEND NHL 001

Further data from the TRANSCEND NHL 001 study supporting the role of CART therapy in mantle cell lymphoma. However it appears the rate of toxicity is just a little higher […]

Lines of Therapy before Autologous Stem Cell Transplant (ASCT) and CAR-T Infusion Affect Outcomes in Aggressive Non-Hodgkin’s Lymphoma (NHL)

This study evaluated the impact of prior lines of therapy on the efficacy of CAR-T and ASCT and found that OS was significantly longer, with a trend toward longer PFS, […]

CAR-T Therapy for Lymphoma with Prophylactic Tocilizumab: Decreased Rates of Severe Cytokine Release Syndrome without Excessive Neurologic Toxicity

Cytokine release syndrome is a well known complication of CAR-T therapy that can be treated with tocilizumab. This poster presents outcomes for patients treated with locally manufactured antiCD19 CAR-T cells […]

One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

This poster presents follow-up data from the pivotal trial of brexucabtagene autoleucel (Tecartus) for mantle cell lymphoma showing that 75.1% of patients who achieve a CR following this CART, retain […]

A Phase II, Open-Label, Single Arm Trial to Assess the Efficacy and Safety of the Combination of Tisagenlecleucel and Ibrutinib in Mantle Cell Lymphoma (TARMAC)

This poster describes a clinical trial of tisagenlecleucel + ibrutinib that is currently recruiting in Australia. The trial allows very early recruitment of patients with MCL+genomic risk factors, or recruitment […]

Privacy Policy © Copyright Bastion Brands 2022